{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T22:08:33Z","timestamp":1788041313692,"version":"build-2784847793"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T00:00:00Z","timestamp":1663977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To undertake a double blinded randomised placebo-controlled trial to assess the efficacy of vigabatrin, a GABA-transaminase inhibitor, as a benzodiazepine sparing agent in the management of acute alcohol withdrawal syndrome in a residential setting.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We enrolled 120 patients with alcohol use disorder who were randomly assigned to either treatment with vigabatrin (2g\/day for 4 days) or placebo. The primary outcome was defined as the number of participants in each treatment arm needing diazepam for withdrawal management. A secondary outcome prespecified was the total dose of diazepam received by participants in each treatment arm. Participants were recruited on admission to a residential withdrawal unit at St Vincent\u2019s Hospital Melbourne from December 2014 to April 2019.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>No significant difference was observed in the number of participants requiring benzodiazepines during their residential withdrawal stay with 44 participants (78.6%) in placebo arm requiring at least one dose of diazepam compared to 38 (66.7%) in vigabatrin arm (p\u2009=\u2009.156). An 18.1% difference was observed between the proportion of participants who received a total dose of &amp;gt;100mg of diazepam during their residential withdrawal stay in placebo arm (32.1%), compared to vigabatrin arm (14.0%, p\u2009=\u2009.022). There were higher rates of reported adverse events in placebo arm with nine (15.0%) participants reporting adverse events compared with two (3.3%) participants in vigabatrin arm (p\u2009=\u2009.027).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Vigabatrin significantly reduced the number of participants requiring &amp;gt;100mg diazepam over the course of their alcohol withdrawal and was associated with a reduction in adverse effects when compared to placebo.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/alcalc\/agac044","type":"journal-article","created":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T07:29:12Z","timestamp":1664177352000},"page":"40-45","source":"Crossref","is-referenced-by-count":3,"title":["A Placebo-Controlled Randomized Trial of Vigabatrin in the Management of Acute Alcohol Withdrawal"],"prefix":"10.1093","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6909-7344","authenticated-orcid":false,"given":"James","family":"Williams","sequence":"first","affiliation":[{"name":"St Vincent\u2019s Hospital Melbourne, Victoria Department of Addiction Medicine, , 41 Victoria Parade, Fitzroy VIC 3065 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Collins","sequence":"additional","affiliation":[{"name":"St Vincent\u2019s Hospital Melbourne, Victoria Department of Addiction Medicine, , 41 Victoria Parade, Fitzroy VIC 3065 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Norman","sequence":"additional","affiliation":[{"name":"St Vincent\u2019s Hospital Melbourne Department of Addiction Medicine, , Victoria, 41 Victoria Parade, Fitzroy VIC 3065 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"O\u2019Neill","sequence":"additional","affiliation":[{"name":"St Vincent\u2019s Hospital Melbourne Department of Addiction Medicine, , Victoria, 41 Victoria Parade, Fitzroy VIC 3065 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martyn","family":"Lloyd-Jones","sequence":"additional","affiliation":[{"name":"St Vincent\u2019s Hospital Melbourne Department of Addiction Medicine, , Victoria, 41 Victoria Parade, Fitzroy VIC 3065 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Ogden","sequence":"additional","affiliation":[{"name":"St Vincent\u2019s Hospital Melbourne Department of Addiction Medicine, , Victoria, 41 Victoria Parade, Fitzroy VIC 3065 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Bonomo","sequence":"additional","affiliation":[{"name":"St Vincent\u2019s Hospital Melbourne Department of Addiction Medicine, , Victoria, 41 Victoria Parade, Fitzroy VIC 3065 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Pastor","sequence":"additional","affiliation":[{"name":"St Vincent\u2019s Hospital Melbourne Department of Addiction Medicine, , Victoria, 41 Victoria Parade, Fitzroy VIC 3065 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,9,24]]},"reference":[{"key":"2023011009063533300_ref1","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1365-2710.2009.01098.x","article-title":"The role of carbamazepine and oxcarbazepine in alcohol withdrawal syndrome","volume":"35","author":"Barrons","year":"2010","journal-title":"J Clin Pharm Ther"},{"key":"2023011009063533300_ref2","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.pbb.2008.03.007","article-title":"The role of GABA(A) receptors in the development of alcoholism","volume":"90","author":"Enoch","year":"2008","journal-title":"Pharmacol Biochem Behav"},{"key":"2023011009063533300_ref3","article-title":"Guidelines for the Treatment of Alcohol Problems","volume":"1","author":"Haber","year":"2009","journal-title":"Australian Government Department of Health and Ageing"},{"key":"2023011009063533300_ref4","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1016\/S0140-6736(97)04572-8","article-title":"The alcohol withdrawal syndrome","volume":"349","author":"Hall","year":"1997","journal-title":"The Lancet"},{"key":"2023011009063533300_ref5","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s40263-015-0240-4","article-title":"Anticonvulsants for the treatment of alcohol withdrawal syndrome and alcohol use disorders","volume":"29","author":"Hammond","year":"2015","journal-title":"CNS Drugs"},{"key":"2023011009063533300_ref6","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1001\/jama.1997.03550020076042","article-title":"Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal","volume":"278","author":"Mayo-Smith","year":"1997","journal-title":"JAMA"},{"key":"2023011009063533300_ref7","first-page":"3","article-title":"Anticonvulsants for alcohol withdrawal. Cochrane Database Systematic","volume":"17","author":"Minozzi","year":"2010","journal-title":"Dent Rev"},{"key":"2023011009063533300_ref8","doi-asserted-by":"crossref","first-page":"2","DOI":"10.13172\/2053-0285-1-1-446","article-title":"Novel anticonvulsants for reducing alcohol consumption: A review of evidence from preclinical rodent drinking models","volume":"1","author":"Padula","year":"2013","journal-title":"OA Alcohol"},{"key":"2023011009063533300_ref9","doi-asserted-by":"crossref","DOI":"10.1016\/j.jemermed.2012.07.056","article-title":"Phenobarbital for Acute Alcohol Withdrawal: A Prospective Randomized Double-blind Placebo-controlled Study","volume":"44","author":"Rosenson","year":"2013","journal-title":"The Journal of Emergency Medicine"},{"key":"2023011009063533300_ref10","article-title":"Baclofen for Alcohol Withdrawal: Not Comparable to the Gold Standard (Benzodiazepines)","volume":"120","author":"Saltz","year":"2007","journal-title":"Am J Med"},{"key":"2023011009063533300_ref11","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/j.1360-0443.1993.tb02093.x","article-title":"Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption-II","volume":"88","author":"Saunders","year":"1993","journal-title":"Addiction"},{"key":"2023011009063533300_ref12","doi-asserted-by":"crossref","first-page":"19s","DOI":"10.1111\/j.1365-2125.1989.tb03456.x","article-title":"Clinical pharmacology of vigabatrin","volume":"27","author":"Schechter","year":"1989","journal-title":"Br J Clin Pharmacol"},{"key":"2023011009063533300_ref13","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/oxfordjournals.alcalc.a008107","article-title":"The Irreversible \u03b3-aminobutyrate transaminase inhibitor, Vigabatrin in the treatment of the alcohol withdrawal syndrome","volume":"31","author":"Stuppaeck","year":"1996","journal-title":"Alcohol Alcohol"},{"key":"2023011009063533300_ref14","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/j.1360-0443.1989.tb00737.x","article-title":"Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar)","volume":"84","author":"Sullivan","year":"1989","journal-title":"Br J Addict"}],"container-title":["Alcohol and Alcoholism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/alcalc\/article-pdf\/58\/1\/40\/48591519\/agac044.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/alcalc\/article-pdf\/58\/1\/40\/48591519\/agac044.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T09:25:13Z","timestamp":1673342713000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/alcalc\/article\/58\/1\/40\/6713281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,24]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,9,24]]},"published-print":{"date-parts":[[2023,1,9]]}},"URL":"https:\/\/doi.org\/10.1093\/alcalc\/agac044","relation":{},"ISSN":["0735-0414","1464-3502"],"issn-type":[{"value":"0735-0414","type":"print"},{"value":"1464-3502","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,1]]},"published":{"date-parts":[[2022,9,24]]}}}